The groundbreaking success of Sildenafil undeniably transformed the pharmaceutical landscape, but investing in companies heavily reliant on unbranded versions presents a uncertain picture. While early returns were substantial, the cessation of patents and the rise of discounted alternatives have weakened sales. Therefore, a thorough assessment of o